Xeltis AG - Product Pipeline Analysis, 2017 Update

  • ID: 4395081
  • Company Profile
  • 29 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Abionic SA
  • Sequana Medical AG
  • Symetis AG
  • MORE
Summary

Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. Its polymer-based technology platform, RestoreX, facilitates the natural restoration of heart valve through a process referred to as endogenous tissue restoration (ETR). Based on supramolecular chemistry, the company develops bioabsorbable synthetic heart valves and vascular grafts to replace defective heart valves and blood vessels. ETR enables the patient’s natural healing system to develop tissue that spreads into the heart valve of Xeltis, building a new and natural valve inside with full functionality. The implants of Xeltis get absorbed by the body in the course of time. The company also operates research and development centers, manufacturing facility in Eindhoven, the Netherlands. Xeltis is headquartered in Zurich, Switzerland.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Xeltis AG
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abionic SA
  • Sequana Medical AG
  • Symetis AG
  • MORE
  • Xeltis AG Company Overview
  • Xeltis AG Company Snapshot
  • Xeltis AG Pipeline Products and Ongoing Clinical Trials Overview
  • Xeltis AG - Pipeline Analysis Overview
  • Xeltis AG - Key Facts
  • Xeltis AG - Major Products and Services
  • Xeltis AG Pipeline Products by Development Stage
  • Xeltis AG Ongoing Clinical Trials by Trial Status
  • Xeltis AG Pipeline Products Overview
  • Endogenous Tissue Growth Implant
  • Endogenous Tissue Growth Implant Product Overview
  • Transcatheter Aortic Heart Valve
  • Transcatheter Aortic Heart Valve Product Overview
  • Xeltis Pulmonary Valve
  • Xeltis Pulmonary Valve Product Overview
  • Xeltis Pulmonary Valve Clinical Trial
  • Xeltis AG - Key Competitors
  • Xeltis AG - Key Employees
  • Xeltis AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
  • Xeltis AG, Recent Developments
  • May 17, 2017: Xeltis' Technology for Natural Heart Valve Restoration Featured as the Future of Valve Therapy at EuroPCR
  • Nov 01, 2016: Xeltis Announces Multidisciplinary Scientific Advisory Board of Global Leading Experts
  • Oct 05, 2016: Patients Implanted with Xeltis Bioabsorbable Cardiovascular Device Showed Positive Functionality Results Two Years After Surgery - Data at EACTS
  • Oct 03, 2016: First Heart Valve That Enables Cardiovascular Restoration Successfully Implanted in Three Patients in “Xplore-I” Clinical Trial
  • May 17, 2016: First Clinical Use of Bioabsorbable Vascular Grafts in Children Shows Promise
  • Mar 23, 2016: US FDA granted Humanitarian Use Device for Xeltis pulmonary valve
  • Nov 10, 2015: Xeltis completed second feasibility clinical trial on bioabsorbable cardiovascular device technology
  • Nov 05, 2015: Eliane Schutte joins the Xeltis Executive Team as Chief Development Officer
  • May 19, 2015: Xeltis Completes First-Ever Study of Endogenous Tissue Growth Technology
  • May 18, 2015: Innovative Cardiovascular Company Xeltis Nominates Michel Darnaud for Election to Its Board of Directors
  • Appendix
  • Methodology
List of Tables
  • Xeltis AG Pipeline Products and Ongoing Clinical Trials Overview
  • Xeltis AG Pipeline Products by Equipment Type
  • Xeltis AG Pipeline Products by Indication
  • Xeltis AG Ongoing Clinical Trials by Trial Status
  • Xeltis AG, Key Facts
  • Xeltis AG, Major Products and Services
  • Xeltis AG Number of Pipeline Products by Development Stage
  • Xeltis AG Pipeline Products Summary by Development Stage
  • Xeltis AG Ongoing Clinical Trials by Trial Status
  • Xeltis AG Ongoing Clinical Trials Summary
  • Endogenous Tissue Growth Implant - Product Status
  • Endogenous Tissue Growth Implant - Product Description
  • Transcatheter Aortic Heart Valve - Product Status
  • Transcatheter Aortic Heart Valve - Product Description
  • Xeltis Pulmonary Valve - Product Status
  • Xeltis Pulmonary Valve - Product Description
  • Xeltis Pulmonary Valve - Prospective, Non-randomized, Open Label Clinical Study to Assess the Feasibility of the Bioabsorbable Pulmonary Valved Conduit in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction
  • Xeltis Pulmonary Valve - Prospective, Non-randomized, Open Label Clinical Study to Assess the Safety of the Bioabsorbable Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction
  • Xeltis AG, Key Employees
  • Xeltis AG, Subsidiaries
  • Glossary
List of Figures
  • Xeltis AG Pipeline Products by Equipment Type
  • Xeltis AG Pipeline Products by Development Stage
  • Xeltis AG Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Symetis AG
  • Sequana Medical AG
  • Abionic SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll